The demonstration that BCR::ABL1 induces CML [6] led to the development of tyrosine kinase inhibitors (TKIs) that target and inhibit the fusion oncoprotein. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.